Ali Behbahani - Jun 17, 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Director
Signature
/s/ Louis Citron, attorney-in-fact
Stock symbol
BDTX
Transactions as of
Jun 17, 2022
Transactions value $
$11,876
Form type
4
Date filed
6/17/2022, 04:35 PM
Previous filing
Jun 16, 2022
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $11.9K +5.85K +60.28% $2.03 15.6K Jun 17, 2022 Direct F1, F2
holding BDTX Common Stock 3.45M Jun 17, 2022 See Note 3 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022.
F3 The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.